Locoid Crelo, emulsion 0.1% 30 g

Pharmaceutical group:

Glucocorticosteroid for topical use.

Pharmic action:

Lokoid Crelo® is a synthetic nonhalogenated glucocorticosteroid drug for topical use. The esterification of the hydrocortisone molecule with an oily acid residue (butyrate) has radically increased the activity of the drug compared to native hydrocortisone. Locoid Crelo® has a fast-onset anti-inflammatory, anti-edematous, antipruritic effect.

The use of Locoid Crelo® in recommended doses does not cause suppression of the hypothalamic-pituitary-adrenal system. Although long-term use of high doses of the drug, especially with occlusive dressings, may increase plasma cortisol levels, this is not usually accompanied by a decrease in pituitary-adrenal reactivity, and withdrawal of the drug leads to rapid normalization of cortisol production.

Pharmacokinetics:

Absorption

After application, the active substance accumulates in the epidermis, mainly in the granular layer, with little systemic absorption. A small amount of hydrocortisone 17-butyrate is absorbed into the systemic bloodstream unchanged.

Metabolism

Most hydrocortisone 17-butyrate is metabolized to hydrocortisone and other metabolites directly in the epidermis and subsequently in the liver.

Elimination

The metabolites and a small portion of unchanged hydrocortisone 17-butyrate are excreted by the kidneys and through the intestine.

Indications

Superficial, non-infected skin diseases sensitive to local corticosteroids:
– eczema;
— dermatitis (including atopic, contact, seborrheic);
– psoriasis.

Pharmacological effect

Pharmaceutical group:

glucocorticosteroid for local use.

Pharmaceutical action:

Locoid Crelo® is a synthetic non-halogenated glucocorticosteroid drug for external use. Esterification of the hydrocortisone molecule with a butyric acid residue (butyrate) made it possible to radically increase the activity of the drug compared to native hydrocortisone. Lokoid Krelo® has a fast-onset anti-inflammatory, anti-edematous, and antipruritic effect.

The use of Locoid Crelo® in recommended doses does not cause suppression of the hypothalamic-pituitary-adrenal system. Although the use of large doses of the drug for a long time, especially when using occlusive dressings, can lead to an increase in plasma cortisol levels, this is usually not accompanied by a decrease in the reactivity of the pituitary-adrenal axis, and drug withdrawal leads to a rapid normalization of cortisol production.

Pharmacokinetics:

Suction

After application, the active substance accumulates in the epidermis, mainly in the granular layer; systemic absorption is negligible. A small amount of hydrocortisone 17-butyrate is absorbed into the systemic circulation unchanged.

Metabolism

Most hydrocortisone 17-butyrate is metabolized to hydrocortisone and other metabolites directly in the epidermis and subsequently in the liver.

Removal

Metabolites and a small part of unchanged hydrocortisone 17-butyrate are excreted by the kidneys and through the intestines.

Special instructions

Avoid contact of the ointment with the eyes. For children under 12 years of age, the drug is prescribed only under strict medical supervision.

If after 7 days of use there is no improvement or worsening of the condition, as well as if symptoms recur a few days after discontinuation, use of the drug should be discontinued and consult a doctor.

The drug should not be used without consulting a doctor in cases where itching in the genital area in women is accompanied by vaginal discharge.

For long-term treatment and/or application to large surfaces, it is recommended to prescribe a diet with limited Na+ and a high content of K+; introduce a sufficient amount of protein into the body.

It is necessary to monitor blood pressure, the concentration of glucose and cortisol in the blood, blood clotting, diuresis, and the patient’s body weight.

Active ingredient

Hydrocortisone

Composition

Active ingredient:

hydrocortisone 17-butyrate;

Excipients:

white soft paraffin – 35 mg,

solid paraffin – 50 mg,

cetomacrogol 25 – 20 mg,

cetostearyl alcohol – 20 mg,

borage oil – 17.5 mg,

propylene glycol – 50 mg,

butylated hydroxytoluene – 0.2 mg,

propyl parahydroxybenzoate – 3 mg,

butyl parahydroxybenzoate – 1.5 mg,

citric acid – 6 mg,

sodium citrate – 5 mg,

purified water – 790.8 mg;

Contraindications

– bacterial skin infections (strepto- and staphyloderma, gram-negative folliculitis);
— viral skin infections (herpes simplex, chicken pox, shingles);
– fungal skin infections;
– tuberculous and syphilitic skin lesions;
– parasitic skin infections;
— neoplastic skin changes (benign and malignant tumors);
— acne, rosacea, perioral dermatitis;
— post-vaccination period;
— violation of the integrity of the skin (wounds, ulcers);
– hypersensitivity to the drug Locoid Crelo.
The drug should be prescribed with caution during pregnancy and lactation.

Side Effects

Local reactions: skin irritation; in rare cases, other local reactions characteristic of GCS therapy.

Systemic reactions: with long-term use, application to large surfaces and/or use of occlusive dressings, side effects characteristic of systemic corticosteroids may be observed.

The risk of local and systemic side effects when using Locoid Crelo® is lower than when using fluorinated steroids.

Overdose

There is no data on an overdose of Locoid Crelo®.

With long-term use of the drug in high doses, the side effects described above may increase.

If symptoms of hypercortisolism appear, the drug should be discontinued.

Storage conditions

The drug should be stored out of the reach of children at a temperature not exceeding 25°C.

Shelf life

2 years.

Manufacturer

Temmler Italia S.r.L., Italy